MedTrace Logo

Impact of Targeted Therapy on Cancer-Related Cognitive Impairment

NCT07638007 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2026-06-10

No results posted yet for this study

Summary

This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for leukemia compared to individuals who do not receive TKI therapy.

Conditions

  • Disease/Condition Name Cancer-related Cognitive Dysfunction
  • Chronic Lymphocytic Leukemia (CLL)
  • Chronic Myeloid Leukemia, BCR-ABL1 Positive

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Rochester NCORP Research Base

    lead OTHER

Principal Investigators

  • Michelle Janelsins, PhD · University of Rochester NCORP Research Base

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-21
Primary Completion
2029-02-28
Completion
2029-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07638007 on ClinicalTrials.gov